吉西他滨联合卡铂治疗晚期非小细胞肺癌

Gemcitabine Combined with Carboplatin in Advanced Stage Non-Small Cell Lung Cancer

目的研究吉西他滨（Gem）联合卡铂（CBP）方案治疗晚期非小细胞肺癌（NSCLC）的疗效和毒副作用。方法经病理学确诊的非小细胞肺癌38例。其中腺癌24例，鳞癌11例，肺泡细胞癌2例，大细胞癌1例。初治34例，复治4例；11期12例（Ⅲa期2例，Ⅲb期10例），Ⅳ期26例。采用吉西他滨1000mg／m^2，第1、8天静滴；卡铂AUC=6，21天为1个周期。结果完全缓解（CR）1例，部分缓解（PR）16例，稳定（SO）11例，进展（PD）10例，总有效率为44．7％。中位进展期6个月，中位生存期14个月，1年生存率53．6％。Ⅲ-Ⅳ度血小板下降36．8％，为主要血液性毒性。结论吉西他滨联合卡铂方案治疗晚期NSCLC疗效确切，肾毒性及胃肠道等毒性反应较少。血液性毒性可以耐受，患者对治疗有较好的依存性，对老年患者尤为适宜，且方便门诊应用。

Objective To evaluate the efficacy and toxicity of Gemeitabine combined with Carboplatin （GC regimen） in the treatment of advanced non-small cell lung Cancer （NSCLC）.Methods Thirty eight patients with advanced NSCLC were confirmed by pathology. There were 24 patients with lung adenocareinoma, 11 patients with squamous carcinoma and 2 patients with alveoli cell cancer, 1 patient with large-cell lung cancer. The thirty four patients had no prior chemotherapy and four patients without received previously chemotherapy. Twelve patients had stage Ⅲ disease and 26 patients had stage Ⅳ. Results Complete response and partial response were observed in 1 and 16 patients respectively, the overall response rate was 44.7%. Median time to progression （TI＇P） was 6 months. Median survival duration was 14 months, one year survival rate was 53.6%. The dose limiting toxicity was thrombocytopenia that was observed in 86.8 % of the patients（36.8 % in grades Ⅲ and Ⅳ ）. Conclusions The results indicated GC regimen for advanced NSCLC is promising, and the toxicities are tolerable.